Sign In
Buy ERAS
$18.15
-0.530 (-2.84%)
At Close: Jul 31, 2026
SAN DIEGO--(BUSINESS WIRE)---- $ERAS #Health--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Erasca, Inc. (NASDAQ: ERAS)
DEADLINE ALERT: Erasca, Inc. (ERAS) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
04:15am, Friday, 17'th Jul 2026
San Diego, California--(Newsfile Corp. - July 17, 2026) - Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Erasca, Inc. (NASDAQ: ERAS) common stock between January 14, 2025 a
LOS ANGELES, July 16, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming August 10, 2026 deadline to file a lead plaintiff motion in the class action filed on
New York, New York--(Newsfile Corp. - July 16, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Erasca, Inc. (NASDAQ: ERAS) between January 14, 20
Bronstein, Gewirtz & Grossman LLC Urges Erasca, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
12:00pm, Thursday, 16'th Jul 2026
New York, New York--(Newsfile Corp. - July 16, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed agains
NEW ORLEANS, July 16, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 10, 2026 to file lead plaintiff applications in a secu
ERAS DEADLINE: SueWallSt Reminds Erasca, Inc. Investors of Upcoming Securities Class Action Deadline
10:07am, Thursday, 16'th Jul 2026
Erasca's repeated preclinical comparisons to Revolution Medicines' RMC-6236 were allegedly improper and placed the company at risk of patent and trade secret violations, costing investors over $11 per
NEW YORK, July 16, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Erasca, Inc. ("Erasca" or the "Company") (NASDAQ: ERAS). Such investors are advise
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Erasca, Inc. (ERAS)
09:16am, Thursday, 16'th Jul 2026
NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or ac
ERAS INVESTOR DEADLINE: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - HBSS
09:00am, Thursday, 16'th Jul 2026
SAN FRANCISCO, July 16, 2026 /PRNewswire/ -- Hagens Berman, a national shareholder rights firm, is actively investigating claims in a class action alleging securities law violations at Erasca, Inc. (N
SAN DIEGO, July 15, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Erasca, Inc. (NASDAQ: ERAS) common stock between January 14, 2025 and April 26, 2
SAN FRANCISCO, July 15, 2026 (GLOBE NEWSWIRE) -- Hagens Berman, a national shareholder rights firm, is actively investigating claims in a class action alleging securities law violations at Erasca, Inc
SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for p
BENSALEM, Pa., July 15, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Erasca To Contact Him Directly To Discuss Their Options If you purchased or acquired
